Creative Medical Technology Holdings, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Creative Medical Technology Holdings, Inc. (CELZ) reported Net Income (Loss) Available to Common Stockholders, Diluted of $18.22 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-11-10
- Creative Medical Technology Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was -$4.86M.
- Creative Medical Technology Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$1.96M, a 563.56% decline year-over-year.
- Creative Medical Technology Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$2.84M.
- Creative Medical Technology Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was $27.89M, a 635.45% increase year-over-year.
- Creative Medical Technology Holdings, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was $18.22M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$6.83M derived: sum of 2 quarters · filed 2022-11-10 | -$9.67M derived: sum of 3 quarters · filed 2022-11-10 | $18.22M 10-K · filed 2022-03-30 |
| 2021-09-30 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$4.80M derived: sum of 2 quarters · filed 2022-11-10 | $23.09M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$2.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $25.05M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $27.89M 10-Q · filed 2022-05-13 | |||
| 2020-09-30 | $423.08K 10-Q · filed 2021-11-15 | -$1.41M derived: sum of 2 quarters · filed 2021-11-15 | $2.40M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.96M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $3.79M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |